Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Fortress Biotech Announces Publication of Study on Targeted Next Generation Sequencing for Newborn Screening of Menkes Disease in Molecular Genetics and Metabolism Reports

Jul 29, 2020

Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration-Enabling Trial at ESMO Virtual Congress 2020

Jul 27, 2020

Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results

Jul 21, 2020

Fortress Biotech Added to Russell 3000® Index

Jun 29, 2020

Fortress Biotech to Present at the Raymond James Human Health Innovation Conference

Jun 15, 2020

Mustang Bio Announces Pricing of Public Offering of Common Stock

Jun 11, 2020

Fortress Biotech Announces Publication of Study on Estimated Birth Prevalence of Menkes Disease in Molecular Genetics and Metabolism Reports

Jun 11, 2020

Mustang Bio Announces Proposed Public Offering of Common Stock

Jun 10, 2020

Avenue Therapeutics Announces Publications in Peer-Reviewed Journals

Jun 05, 2020

Mustang Bio to Host Virtual Annual Meeting of Stockholders

Jun 04, 2020
RSS
  • Prev
    • 1...
    • 39
    • 40
    • 41
    • 42
    • 43
    • 44
    • 45
    • 46
    • 47
    • 48
    • ...71
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2025 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap